Metabolic phenotyping to monitor chronic enteritis canceration.
Metabolic phenotyping to monitor chronic enteritis canceration.
复制标题
代谢表型监测慢性肠炎癌变。
DOI：
10.1007/s11306-020-1651-x
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Li Kang
中科院分区：
文献类型：
--
作者：
Zhang Fan;Li Chunbo;Deng Kui;Wang Zhuozhong;Zhao Weiwei;Yang Kai;Yang Chunyan;Rong Zhiwei;Cao Lei;Lu Yaxin;Huang Yue;Han Peng;Li Kang
IntroductionColorectal cancer (CRC) remains an incurable disease. Previous metabolomic studies show that metabolic signatures in plasma distinguish CRC patients from healthy controls. Chronic enteritis (CE) represents a risk factor for CRC, with a 20 fold greater incidence than in healthy individuals. However, no studies have performed metabolomic profiling to investigate CRC biomarkers in CE.ObjectiveOur aims were to identify metabolomic signatures in CRC and CE and to search for blood-derived metabolite biomarkers distinguishing CRC from CE, especially early-stage biomarkers.MethodsIn this case–control study, 612 subjects were prospectively recruited between May 2015 and May 2016, and including 539 CRC patients (stage I, 102 cases; stage II, 259 cases; stage III, 178 cases) and 73 CE patients. Untargeted metabolomics was performed to identify CRC-related metabolic signatures in CE.ResultsFive pathways were significantly enriched based on 153 differential metabolites between CRC and CE. 16 biomarkers were identified for diagnosis of CRC from CE and for guiding CRC staging. The AUC value for CRC diagnosis in the external validation set was 0.85. Good diagnostic performances were also achieved for early-stage CRC (stage I and stage II), with an AUC value of 0.84. The biomarker panel could also stage CRC patients, with an AUC of 0.72 distinguishing stage I from stage II CRC and AUC of 0.74 distinguishing stage II from stage III CRC.ConclusionsThe identified metabolic biomarkers exhibit promising properties for CRC monitoring in CE patients and are superior to commonly used clinical biomarkers (CEA and CA19-9).
